Journal of Nephropharmacology最新文献_第9页

The nephroprotective effect of Eryngium caucasicum extract alone and in combination with metformin in adult male diabetic rats 白芍提取物单用及联用二甲双胍对成年雄性糖尿病大鼠的肾保护作用

Journal of Nephropharmacology Pub Date : 2021-01-13 DOI: 10.34172/npj.2022.10379

Elnaz Golestaneh, A. Hasanpour Dehkordi, Banafsheh Yalameha, P. Noorshargh, Parto Nasri, A. Baradaran

{"title":"The nephroprotective effect of Eryngium caucasicum extract alone and in combination with metformin in adult male diabetic rats","authors":"Elnaz Golestaneh, A. Hasanpour Dehkordi, Banafsheh Yalameha, P. Noorshargh, Parto Nasri, A. Baradaran","doi":"10.34172/npj.2022.10379","DOIUrl":"https://doi.org/10.34172/npj.2022.10379","url":null,"abstract":"Introduction: Diabetes mellitus (DM) is a metabolic disease associated with the disorders in the metabolism of carbohydrates, proteins, and lipids that affect insulin action. Objectives: The present study was designed to evaluate the nephroprotective effect of Eryngium caucasicum (Eryngo) extract alone and in combination with metformin (MET) in adult male diabetic rats. Materials and Methods: Thirty male Wistar rats randomly were designated into five groups (n = 6) including; group I (Control); rats received normal saline by gavage for 15 days. Group II; rats received a single injection of STZ at a dose of 60 mg/kg intraperitoneally. Group III; rats, after STZ injection, received 30 mg/kg of MET by gavage for 15 days. Group IV; rats, after STZ injection, received 30 ml/kg of Eryngo extract by gavage for 15 days. Group V; rats, after STZ injection, received the combination of MET and Eryngo extract at a dose of 30 mg/kg by gavage for 15 days. The kidneys were removed immediately after sacrificing and prepared for morphological examination. Kidney sections were examined for the intensity of kidney damage (vacuolization, flattening, degeneration, and necrosis). Results: Significant differences were observed in types of morphologic injury to renal tubular cells between groups (P < 0.05). Eryngo extract had more protective effect against kidney damage due to DM compared to MET and the combination of MET+Eryngo. Additionally, in pairwise comparisons of groups, the relationship between group II (DM group) and group IV (DM + Eryngo) was significant (P < 0.05). Conclusion: The administration of MET and Eryngo extract alone and their combination ameliorate types of morphologic injury to renal tubular cells in diabetic rats, however, the renoprotective effect of Eryngo extract alone is more remarkable.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43343681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Angiotensin 1-7 and losartan worsen the cisplatin induced nephrotoxicity in female rats 血管紧张素1-7和氯沙坦加重顺铂诱导的雌性大鼠肾毒性

Journal of Nephropharmacology Pub Date : 2021-01-13 DOI: 10.34172/npj.2022.10

S.mehrdad Kasaei, Zahra Pezeshki, F. Karimi, Z. Lak, S. Choopani, A. Talebi, M. Nematbakhsh

{"title":"Angiotensin 1-7 and losartan worsen the cisplatin induced nephrotoxicity in female rats","authors":"S.mehrdad Kasaei, Zahra Pezeshki, F. Karimi, Z. Lak, S. Choopani, A. Talebi, M. Nematbakhsh","doi":"10.34172/npj.2022.10","DOIUrl":"https://doi.org/10.34172/npj.2022.10","url":null,"abstract":"\u0000 Introduction: Cisplatin (CP) is an anti-cancer drug with the most common side effects of nephrotoxicity. Losartan, an angiotensin II type 1 receptor (AT1R) antagonist and angiotensin 1-7 (Ang1-7) protects the kidney against CP administration in males Moreover, the activity of the renin angiotensin system (RAS) and the incidence of CP induced nephrotoxicity are gender related. Objectives: The role of Ang1-7 and losartan against CP induced nephrotoxicity in female rats was examined. Methods: Thirty-two female Wistar rats in five experimental groups were treated with vehicle, single dose of CP (7.5 mg/kg), CP+losartan (10 ), CP+Ang1-7 (30 μg/kg/d) or CP+Ang1-7+A779 (Mas receptor antagonist, 100 μg/kg/d). The biochemical and histology measurements were conducted one week later. Results: The levels of serum creatinine (Cr) and blood urea nitrogen (BUN) in serum increased insignificantly by CP alone administration. However co-treatment of CP with losartan, Ang1-7, or Ang1-7 plus A779 showed an increase of the serum levels of BUN and Cr, and kidney tissue damage score (KTDS) (P < 0.05) when compared with control groups. Conclusion: The AT1R and Mas receptor (MasR) antagonists and Ang1-7 administration promote the CP induced damage of kidney in female rats, and special attention is needed during CP therapy in hypertensive patients who are treating with anti-hypertensive drug of losartan.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45455539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Understanding kidney injury in COVID-19; a pressing priority 了解COVID-19肾损伤;当务之急

Journal of Nephropharmacology Pub Date : 2020-11-26 DOI: 10.34172/npj.2021.19

Elham Ahmadipour, B. Lakkakula, Golnaz Vahdani, R. Tolouian, Hedieh Ragati Haghi, D. Delgado, Luiz Augusto Fernandes da Silva, M. Hafizi

引用次数: 2

Herbal medicines in the treatment of coronavirus disease 2019 (COVID-19) 中草药治疗2019冠状病毒病(COVID-19)

Journal of Nephropharmacology Pub Date : 2020-11-02 DOI: 10.34172/NPJ.2021.18

Audrey Tolouian, M. Khosravian, Hedieh Ragati Haghi, A. Bolourian, Z. Mojtahedi, Masoumeh Asgharpour, Amirhesam Alirezaei

{"title":"Herbal medicines in the treatment of coronavirus disease 2019 (COVID-19)","authors":"Audrey Tolouian, M. Khosravian, Hedieh Ragati Haghi, A. Bolourian, Z. Mojtahedi, Masoumeh Asgharpour, Amirhesam Alirezaei","doi":"10.34172/NPJ.2021.18","DOIUrl":"https://doi.org/10.34172/NPJ.2021.18","url":null,"abstract":"Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus, started in livestock within the markets of Wuhan, China and was consequently spread around the world. The virus has been rapidly spread worldwide due to the outbreak. COVID-19 is the third serious coronavirus outbreak in less than 20 years after Severe Acute Respiratory Syndrome (SARS) in 2003 and Middle East Respiratory Syndrome (MERS) in 2012. The novel virus has a nucleotide identity closer to that of the SARS coronavirus than that of the MERS coronavirus. Since there is still no vaccine, the main ways to improve personal immunity against this disease are prophylactic care and self-resistance including an increased personal hygiene, a healthy lifestyle, an adequate nutritional intake, a sufficient rest, and wearing medical masks and increasing time spent in well ventilated areas. There is a need for novel antivirals that are highly efficient and economical for the management and control of viral infections when vaccines and standard therapies are absent. Herbal medicines and purified natural products have the potential to offer some measure of resistance as the development of novel antiviral drugs continues. In this review, we evaluated 41 articles related to herbal products which seemed to be effective in the prevention or treatment of COVID-19.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47593168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

ADAMTS13 gene; a novel splicing site mutation in a case with thrombotic thrombocytopenic purpura ADAMTS13基因；一例血栓性血小板减少性紫癜的新剪接位点突变

Journal of Nephropharmacology Pub Date : 2020-10-30 DOI: 10.34172/NPJ.2021.17

S. Zununi Vahed, Alessandra Cremaschi, Behzad Zaker, Seyed Sadroddin Rasi Hashemi, M. Ardalan

引用次数: 0

Potential of renin-angiotensin system inhibition to improve metabolic bone disorders 肾素-血管紧张素系统抑制改善代谢性骨疾病的潜力

Journal of Nephropharmacology Pub Date : 2020-10-17 DOI: 10.34172/NPJ.2021.16

M. Momenzadeh, M. Khosravian, B. Lakkakula

引用次数: 9

Evaluation of urinary NGAL level in children with congenital heart disease as a possible early indicator of nephropathy 先天性心脏病患儿尿NGAL水平作为肾病早期指标的评估

Journal of Nephropharmacology Pub Date : 2020-09-14 DOI: 10.34172/NPJ.2021.14

H. Momtaz, A. Tanasan, Majid Godini

{"title":"Evaluation of urinary NGAL level in children with congenital heart disease as a possible early indicator of nephropathy","authors":"H. Momtaz, A. Tanasan, Majid Godini","doi":"10.34172/NPJ.2021.14","DOIUrl":"https://doi.org/10.34172/NPJ.2021.14","url":null,"abstract":"\u0000 Introduction: Nephropathy as a consequence of congenital heart disease (CHD), especially cyanotic heart disease, has been detected since past decades. However, lack of a diagnostic method at early stages of the disease, caused patients referring when nephropathy is established and also complicated with severe proteinuria and renal failure. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is known as one of the newest biomarkers for early detection of renal parenchymal damage. In this study, we attempted to evaluate the role of urinary NGAL level in early detection of nephropathy in pediatrics with CHD. Objectives: The aim of this study was to evaluate urinary NGAL as a potential biomarker for the early detection of renal involvement in children with CHD. Patients and Methods: In this case–control study, urinary NGAL levels of 42 children with CHD (case group) and 42 healthy children (control group) with the matched ages were measured. Afterward, we compared mean urinary NGAL levels between these two groups to find a possible significant difference. Results: In this study, mean urinary NGAL level in patients with CHD and healthy children was 3.83 μg/mL and 1.87 μg/mL, respectively. Although the mean urine NGAL level was higher in children with CHD compared to healthy children, this difference was not statistically significant. Conclusion: in this study, it can be concluded that, urinary NGAL level cannot be used as an early diagnostic test of nephropathy in children with CHD.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49614637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The predictability of mean platelet volume as a biomarker of pyelonephritis among pediatrics with urinary tract infection 平均血小板体积作为儿童尿路感染肾盂肾炎生物标志物的可预测性

Journal of Nephropharmacology Pub Date : 2020-09-14 DOI: 10.34172/NPJ.2021.15

M. Razavi, Kamal Eshagh Hossaini, Neda Bayatani, Mohsen Akhavan Sepahi, S. Arsang-Jang

{"title":"The predictability of mean platelet volume as a biomarker of pyelonephritis among pediatrics with urinary tract infection","authors":"M. Razavi, Kamal Eshagh Hossaini, Neda Bayatani, Mohsen Akhavan Sepahi, S. Arsang-Jang","doi":"10.34172/NPJ.2021.15","DOIUrl":"https://doi.org/10.34172/NPJ.2021.15","url":null,"abstract":"\u0000 Introduction: Delayed diagnosis of acute pyelonephritis and its differentiation from cystitis can lead to irreversible complications in renal tissue, hypertension and even renal failure. Objectives: The present study aimed to evaluate the diagnostic value of platelet volume in acute pyelonephritis. Patients and Methods: This cross-sectional study was conducted on 110 children with febrile acute urinary tract infection (UTI) referred to our educational hospital in Qom, Iran. Individuals with inclusion criteria were examined for mean platelet volume (MPV), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) and platelet counts. Additionally, Tc 99m-dimercaptosuccinic acid scan (DMSA scan) was used as the gold standard for differentiation of cystitis from acute pyelonephritis. Urine culture was also used to confirm diagnosis of UTI. Results: The mean age of the participants was two years with a range of two months to 13 years. The MPV (P=0.001), CRP (P=0.001), ESR (P=0.001), platelet (P=0.013) and WBC count (P=0.001) were significantly higher in the pyelonephritis group compared to cystitis group. We showed that MPV has similar potency in differentiating pyelonephritis from cystitis compared to other inflammatory markers; however CRP was more accurate than other markers. The cut-off point for MPV was estimated 7.8 fl, with sensitivity of 91%, specificity of 92.7%, and positive predictive value of 92.6%. Conclusion: The high level of ESR is a risk factor to develop pyelonephritis. MPV as an inflammatory marker is similar to that of other inflammatory markers in segregating pyelonephritis in children, although further studies are needed to confirm the results of this study.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47515754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metformin induced acute kidney injury; a systematic review 二甲双胍诱导的急性肾损伤；系统综述

Journal of Nephropharmacology Pub Date : 2020-09-09 DOI: 10.34172/NPJ.2021.13

M. Momenzadeh, B. Lakkakula

{"title":"Metformin induced acute kidney injury; a systematic review","authors":"M. Momenzadeh, B. Lakkakula","doi":"10.34172/NPJ.2021.13","DOIUrl":"https://doi.org/10.34172/NPJ.2021.13","url":null,"abstract":"\u0000 Introduction: Metformin is the best proven first-line treatment for type 2 diabetes (T2DM), based on both national and international guidelines. The present systematic review is aimed to examine the acute kidney injury (AKI) risk associated with metformin. Methods: A systematic literature search was performed in MEDLINE, PubMed and google scholar, to retrieve the literature related to the metformin use. A bibliographic management software (Endnote X9) was used for managing the literature. The following keywords were used: \"Acute renal injury OR ARI\", \"Acute kidney injury OR AKI\",\" Metformin\", \" Type 2 diabetes mellitus OR T2DM\", \"Diabetic patients\", \"Renal function\", \"CKD\". Results: About 28 relevant articles were found during the electronic and manual search. Finally, a total of four articles that fulfill the inclusion criteria were used for this systematic literature review. There is no evidence to suggest that metformin increases the incidence of AKI and is associated with an increased survival of 28 days following AKI event. Further, there was no difference in the incidence of AKI in patients who continued metformin after arterial contrast exposure compared with the control group. Conclusion: In summary, there is no evidence that metformin increases the incidence of AKI. More clinical trials are needed in this area, to investigate more evidence so that we can better understand the outcome.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41311065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Strive for kidney health for everyone during COVID-19; the possible theme for the world kidney day 2021 在COVID-19期间，为每个人的肾脏健康而努力;2021年世界肾脏日可能的主题

Journal of Nephropharmacology Pub Date : 2020-09-07 DOI: 10.34172/npj.2021.12

Elahe Aleebrahim-Dehkordi, E. Mazaheri, B. Roshan, B. Lakkakula, A. Hasanpour-Dehkordi, M. Khosravian, A. Pezeshgi

引用次数: 1